{"schema_version":"secwatch.filing_event.v1","accession":"0001380106-24-000058","form_type":"8-K","ticker":"RPID","cik":"0001380106","company_name":"RAPID MICRO BIOSYSTEMS, INC.","filed_at":"2024-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.005493+00:00","generated_at":"2026-06-05T05:22:26.425485+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rapid Micro Biosystems Q4 revenue $6.3M (+45% YoY); guides FY2024 revenue ≥$27M","bullets":["Q4 2023 revenue $6.3M (+45% YoY); placed 6 Growth Direct systems, highest since Q3 2021.","FY2023 revenue $22.5M (+31% YoY); net loss $52.5M vs $60.8M in 2022, loss narrowed.","Gross margin improved to near breakeven (-3%) from -59% in Q4 2022 on cost actions.","Cash $95M, no debt; expected runway into H2 2026.","FY2024 guidance: revenue ≥$27M, at least 20 system placements; new Rapid Sterility app by mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001380106-24-000058","json":"https://secwatch.observer/filing/0001380106-24-000058.json","markdown":"https://secwatch.observer/filing/0001380106-24-000058.md","text":"https://secwatch.observer/filing/0001380106-24-000058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1380106/000138010624000058/0001380106-24-000058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1380106/000138010624000058/rpid-20240301.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T05:22:26.425485+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d25ed1c5375d645a54b0220ea3a60410bd0eed88","claim":"RAPID MICRO BIOSYSTEMS, INC. updated its fourth quarter and fiscal year ended December 31, 2023 guidance (initiated).","evidence_excerpt":"On March 1, 2024, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its fourth quarter and fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1380106/000138010624000058/0001380106-24-000058-index.htm","confidence":0.92,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and fiscal year ended December 31, 2023"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}